Charles E. Inturrisi, PhD, is affiliated with Relmada Therapeutics, Inc, Coral Gables, Florida. His publications focus on the safety and efficacy of esmethadone in patients with major depressive disorder, including studies on long-term treatment and phase 3 randomized controlled trials involving patients with inadequate response to standard antidepressants. His work has appeared in Psychiatrist.com between 2024 and 2025.
Physicians Postgraduate Press, Inc. (PPP) makes no warranties about the accuracy or completeness of any information published in The Journal of Clinical Psychiatry or other PPP materials, and disclaims liability for any use or non-use of that information. Clinicians should not rely solely on these materials and should exercise their own professional judgment when making patient care decisions on an individualized basis.
